A Phase 3 interventional study of pegloticase 8 mg i.v. in Chronic Gout Refractory to Conventional Therapy, sponsored by Savient Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.
Sponsored by Savient Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.
Among the 14 studies testing pegloticase in Gout, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 4th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 93 across the 14 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 4 most frequent:
Savient Pharmaceuticals is the lead sponsor of 6 studies on the registry; none are open to participants now.
Savient Pharmaceuticals has 4 studies filed under Gout — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pegloticase in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry.
This study is limited to four study centers in the US.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pegloticase 8 mg i.v.
pegloticase 8 mg i.v. every 2 weeks for 24 weeks
Adverse Event Profile
Number of participants reporting events
Time frame: 6 months
Mean Plasma Uric Acid
This endpoint assessed the change in mean PUA concentration from baseline after the first dose and after the third dose. Mean PUA was calculated from samples collected at 5 timepoints following each of those doses. For example, Mean PUA at Week 3 included 5 timepoints before dose 2 infusion.
Time frame: Baseline, Week 3 and Week 7
| Milestone | Pegloticase 8 mg Every 2 Wks |
|---|---|
| Started | 7 |
| Completed | 4 |
| Not completed | 3 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Adverse event | 1 |
Number of participants reporting events
| Number of participants | Pegloticase 8 mg Every 2 Wks |
|---|---|
| Adverse Events | 7 |
| Serious Adverse Events | 2 |
This endpoint assessed the change in mean PUA concentration from baseline after the first dose and after the third dose. Mean PUA was calculated from samples collected at 5 timepoints following each of those doses. For example, Mean PUA at Week 3 included 5 timepoints before dose 2 infusion.
| mg/dL | Pegloticase 8 mg Every 2 Wks |
|---|---|
| Baseline | 8.5 ± 1.21 |
| Week 3 | 4.0 ± 2.63 |
| Week 7 | 7.7 ± 5.61 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegloticase 8 mg Every 2 Wks | — | — | 7/7 (100%) |
| Event | Pegloticase 8 mg Every 2 Wks |
|---|---|
| CellulitisInfections and infestations | 1/7 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/7 |
| Event | Pegloticase 8 mg Every 2 Wks |
|---|---|
| Gout (flare)Musculoskeletal and connective tissue disorders | 5/7 |
| Infusion-Related ReactionGeneral disorders | 4/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/7 |
| FatigueGeneral disorders | 1/7 |
| Oedema PeripheralGeneral disorders | 1/7 |
| Back PainMusculoskeletal and connective tissue disorders | 1/7 |
| Shoulder PainMusculoskeletal and connective tissue disorders | 1/7 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/7 |
| NauseaGeneral disorders | 1/7 |
| VomitingGastrointestinal disorders | 1/7 |
| Age, Categorical(Participants) | Pegloticase 8 mg Every 2 Wks |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 3 |
| Age Continuous(years) | Pegloticase 8 mg Every 2 Wks |
|---|---|
| Mean | 66.4 ± 8.77 |
| Sex: Female, Male(Participants) | Pegloticase 8 mg Every 2 Wks |
|---|---|
| Female | 1 |
| Male | 6 |
| Region of Enrollment(participants) | Pegloticase 8 mg Every 2 Wks |
|---|---|
| United States | 7 |
The record gives a start of May 2008, a primary completion of Jan 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegloticase
Savient Pharmaceuticals